MRK - יחס חוב להיוון בספרים Merck Sharp & Dohme

The stable moat of Merck & Co., Inc. (MRK) is constrained by patent cliff risks, which drives increased R&D investment. Total debt relative to book capitalization, the latter of which stands at 1.39, demonstrates financial resilience. This is further supported by pipeline transparency and the high professionalism of top management. The holding's ecosystem relies on critical vaccines and cutting-edge oncology developments, ensuring the systemic importance of the business.

To stress-test assets, an investor evaluates the total liabilities-to-equity ratio to determine business resilience during crises and the speed of balance sheet deleveraging. By analyzing the percentage of debt participation in balance sheet capital, one can understand to what extent borrowed funds for M&A and the development of the Keytruda oncology portfolio do not burden the financial stability of Merck & Co., Inc. (MRK) amid patent dependency.